|
|
| Line 1: |
Line 1: |
| ==General==
| | #REDIRECT[[Oseltamivir]] |
| *Type: Antiviral - neuraminidase inhibitor
| |
| *Dosage Forms: capsule (30, 45, 75mg), powder for PO susp (6mg/mL)
| |
| *Common Trade Names: Tamiflu
| |
| | |
| ==Adult Dosing==
| |
| ===[[Influenza]]===
| |
| 75mg PO BID x5d
| |
| | |
| ==Pediatric Dosing==
| |
| ''5 day course''
| |
| *1-8 months: 3mg/kg PO BID
| |
| *9-23 months: 3.5mg/kg PO BID
| |
| *2-12 years:
| |
| **<15kg: 30mg PO BID
| |
| **16-23kg: 45mg PO BID
| |
| **24-40kg: 60mg PO BID
| |
| **>40kg: 75mg PO BID
| |
| | |
| ==Special Populations==
| |
| *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: Category C
| |
| *Lactation: Unknown; caution required
| |
| *Renal Dosing
| |
| **Adult
| |
| **Pediatric
| |
| *Hepatic Dosing
| |
| **Adult
| |
| **Pediatric
| |
| | |
| ==Contraindications==
| |
| *Allergy to class/drug
| |
| | |
| ==Adverse Reactions==
| |
| ===Serious===
| |
| Rare <1%
| |
| | |
| Arrhythmia, delirium, hemorrhagic colitis, hepatitis, seizure, TEN, SJS, angioedema, unstable angina, pseudomembranous colitis
| |
| | |
| ===Common===
| |
| Abdominal pain, insomnia, nausea, vomitting, vertigo, epistaxis, ear complaints, conjunctivitis.
| |
| | |
| ==Pharmacology==
| |
| *Half-life: 1-3 hrs (oseltamivir); 6-10hrs oseltamivir carboxylate)
| |
| *Metabolism: hepatic
| |
| *Excretion: urine/stool
| |
| *Mechanism of Action: competitive inhibition of influenza virus neuraminidase enzyme, effectively halting viral release from infected cells and passing through mucus membranes.
| |
| | |
| ==See Also==
| |
| | |
| | |
| ==References==
| |
| <references/>
| |
| | |
| [[Category:Pharmacology]]
| |
